<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:49:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6988765" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6988765</identifier>
        <datestamp>2020-02-03</datestamp>
        <setSpec>sctm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Stem Cells Transl Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Stem Cells Transl Med</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2157-6580</journal-id>
              <journal-id journal-id-type="publisher-id">SCT3</journal-id>
              <journal-title-group>
                <journal-title>Stem Cells Translational Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2157-6564</issn>
              <issn pub-type="epub">2157-6580</issn>
              <publisher>
                <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
                <publisher-loc>Hoboken, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6988765</article-id>
              <article-id pub-id-type="pmcid">PMC6988765</article-id>
              <article-id pub-id-type="pmc-uid">6988765</article-id>
              <article-id pub-id-type="pmid">31774626</article-id>
              <article-id pub-id-type="doi">10.1002/sctm.18-0273</article-id>
              <article-id pub-id-type="publisher-id">SCT312626</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Fetal and Neonatal Stem Cells</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Fetal and Neonatal Stem Cells</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Intranasal delivery of human umbilical cord Wharton's jelly mesenchymal stromal cells restores lung alveolarization and vascularization in experimental bronchopulmonary dysplasia</article-title>
                <alt-title alt-title-type="left-running-head">Moreira et al.</alt-title>
                <alt-title alt-title-type="right-running-head">Intranasal delivery of MSCs for BPD</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="sct312626-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Moreira</surname>
                    <given-names>Alvaro</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3455-6608</contrib-id>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>moreiraa@uthscsa.edu</email>
                  </address>
                </contrib>
                <contrib id="sct312626-cr-0002" contrib-type="author">
                  <name>
                    <surname>Winter</surname>
                    <given-names>Caitlyn</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0003" contrib-type="author">
                  <name>
                    <surname>Joy</surname>
                    <given-names>Jooby</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0004" contrib-type="author">
                  <name>
                    <surname>Winter</surname>
                    <given-names>Lauryn</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0005" contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Maxwell</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0006" contrib-type="author">
                  <name>
                    <surname>Noronha</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0007" contrib-type="author">
                  <name>
                    <surname>Porter</surname>
                    <given-names>Melissa</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0008" contrib-type="author">
                  <name>
                    <surname>Quim</surname>
                    <given-names>Kayla</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0009" contrib-type="author">
                  <name>
                    <surname>Corral</surname>
                    <given-names>Alexis</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0010" contrib-type="author">
                  <name>
                    <surname>Alayli</surname>
                    <given-names>Yasmeen</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0011" contrib-type="author">
                  <name>
                    <surname>Seno</surname>
                    <given-names>Tyrelle</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0012" contrib-type="author">
                  <name>
                    <surname>Mustafa</surname>
                    <given-names>Shamimunisa</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0013" contrib-type="author">
                  <name>
                    <surname>Hornsby</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sct312626-cr-0014" contrib-type="author">
                  <name>
                    <surname>Ahuja</surname>
                    <given-names>Sunil</given-names>
                  </name>
                  <xref ref-type="aff" rid="sct312626-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="sct312626-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Pediatrics, Cellular and Integrative Physiology</named-content>
                <institution>University of Texas Health Science Center San Antonio (UTHSCSA)</institution>
                <city>San Antonio</city>
                <named-content content-type="country-part">Texas</named-content>
              </aff>
              <aff id="sct312626-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Microbiology and Immunology</named-content>
                <institution>University of Texas Health Science Center San Antonio (UTHSCSA)</institution>
                <city>San Antonio</city>
                <named-content content-type="country-part">Texas</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Alvaro Moreira, MD, MSc, Department of Pediatrics, Division of Neonatology, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229.<break/>
Email: <email>moreiraa@uthscsa.edu</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>11</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>2</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>2</issue>
              <issue-id pub-id-type="doi">10.1002/sct3.v9.2</issue-id>
              <fpage>221</fpage>
              <lpage>234</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>11</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>9</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 AlphaMed Press <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. <sc>stem cells translational medicine</sc> published by Wiley Periodicals, Inc. on behalf of AlphaMed Press</copyright-statement>
                <license license-type="creativeCommonsBy">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:SCT3-9-221.pdf"/>
              <abstract>
                <title>Abstract</title>
                <p>Bronchopulmonary dysplasia (BPD) is a devastating lung condition that develops in premature newborns exposed to prolonged mechanical ventilation and supplemental oxygen. Significant morbidity and mortality are associated with this costly disease and effective therapies are limited. Mesenchymal stem/stromal cells (MSCs) are multipotent cells that can repair injured tissue by secreting paracrine factors known to restore the function and integrity of injured lung epithelium and endothelium. Most preclinical studies showing therapeutic efficacy of MSCs for BPD are administered either intratracheally or intravenously. The purpose of this study was to examine the feasibility and effectiveness of human cord tissue‐derived MSC administration given via the intranasal route. Human umbilical cord tissue MSCs were isolated, characterized, and given intranasally (500 000 cells per 20 μL) to a hyperoxia‐induced rat model of BPD. Lung alveolarization, vascularization, and pulmonary vascular remodeling were restored in animals receiving MSC treatment. Gene and protein analysis suggest the beneficial effects of MSCs were attributed, in part, to a concerted effort targeting angiogenesis, immunomodulation, wound healing, and cell survival. These findings are clinically significant, as neonates who develop BPD have altered alveolar development, decreased pulmonary vascularization and chronic inflammation, all resulting in impaired tissue healing. Our study is the first to report the intranasal delivery of umbilical cord Wharton's jelly MSCs in experimental BPD is feasible, noninvasive, and an effective route that may bear clinical applicability.</p>
              </abstract>
              <abstract abstract-type="graphical">
                <p>Intranasal delivery of human umbilical cord mesenchymal stromal cells improves lung growth and development in a rat model mimicking neonatal lung disease.<boxed-text position="anchor" content-type="graphic" id="sct312626-blkfxd-0001" orientation="portrait"><graphic xlink:href="SCT3-9-221-g007.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="sct312626-kwd-0001">bronchopulmonary dysplasia</kwd>
                <kwd id="sct312626-kwd-0002">intranasal delivery</kwd>
                <kwd id="sct312626-kwd-0003">mesenchymal stromal cell</kwd>
                <kwd id="sct312626-kwd-0004">neonate</kwd>
                <kwd id="sct312626-kwd-0005">umbilical cord</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Francis Family Foundation </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/100005834</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>UTHSCSA School of Medicine Clinical Investigator Kickstart Pilot Grant</funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>KL2TR001118</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="0"/>
                <page-count count="14"/>
                <word-count count="9506"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>February 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.5 mode:remove_FC converted:29.01.2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="sct312626-cit-9001"><string-name><surname>Moreira</surname><given-names>A</given-names></string-name>, <string-name><surname>Winter</surname><given-names>C</given-names></string-name>, <string-name><surname>Joy</surname><given-names>J</given-names></string-name>, et al. <article-title>Intranasal delivery of human umbilical cord Wharton's jelly mesenchymal stromal cells restores lung alveolarization and vascularization in experimental bronchopulmonary dysplasia</article-title>. <source xml:lang="en">STEM CELLS Translational Medicine</source>. <year>2020</year>;<volume>9</volume>:<fpage>221</fpage>–<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1002/sctm.18-0273</pub-id>
</mixed-citation>
              </p>
              <fn-group>
                <fn id="sct312626-note-1002">
                  <p><bold>Funding information</bold> Francis Family Foundation; UTHSCSA School of Medicine Clinical Investigator Kickstart Pilot Grant; National Institutes of Health, Grant/Award Number: KL2TR001118</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="sct312626-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="sct312626-blkfxd-0002" orientation="portrait">
                <caption>
                  <title>Significance statement</title>
                </caption>
                <p>Bronchopulmonary dysplasia (BPD) is the most common cause of morbidity and mortality in extremely premature neonates. Unfortunately, current therapies for BPD are limited. Preclinical studies have shown that mesenchymal stem cell (MSC) treatment can restore alveolar growth, enhance vascular development, and stimulate tissue repair. Most of these studies have administered the cells via the intravenous/tracheal route. Results of this study show, for the first time to the authors' knowledge, that the intranasal delivery of MSCs for BPD is effective in restoring lung alveolar growth and vascular development. Importantly, this study provides evidence that this noninvasive approach may be given separately or as an adjunct/alternate to other routes.</p>
              </boxed-text>
            </p>
            <sec id="sct312626-sec-0003">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Preterm birth is a major health concern affecting approximately 12% of all deliveries in the United States and costing over $26 billion every year.<xref rid="sct312626-bib-0001" ref-type="ref">1</xref> The most common cause of morbidity in premature neonates is a devastating lung disease known as bronchopulmonary dysplasia (BPD).<xref rid="sct312626-bib-0002" ref-type="ref">2</xref> BPD is characterized by a simplification of lung development following long‐term exposure to mechanical ventilation and supplemental oxygen, both essential treatments for extremely preterm neonates.<xref rid="sct312626-bib-0003" ref-type="ref">3</xref>, <xref rid="sct312626-bib-0004" ref-type="ref">4</xref> Neonates who develop BPD are at increased risk for cognitive impairment, frequent hospitalizations, and lifelong cardiopulmonary disease.<xref rid="sct312626-bib-0005" ref-type="ref">5</xref>, <xref rid="sct312626-bib-0006" ref-type="ref">6</xref>, <xref rid="sct312626-bib-0007" ref-type="ref">7</xref> The pathophysiology of BPD is complex and encompasses multiple processes including inflammation, oxidative stress, abnormal vasculogenesis, and impaired lung repair.<xref rid="sct312626-bib-0008" ref-type="ref">8</xref>, <xref rid="sct312626-bib-0009" ref-type="ref">9</xref>, <xref rid="sct312626-bib-0010" ref-type="ref">10</xref> Effective treatment options are limited, leaving a vulnerable patient population with an unmet need to develop novel therapies.</p>
              <p>Regenerative medicine is an emerging field that seeks to remedy complex disease states by “stimulating previously irreparable organs to heal themselves.”<xref rid="sct312626-bib-0011" ref-type="ref">11</xref>, <xref rid="sct312626-bib-0012" ref-type="ref">12</xref> Mesenchymal stem/stromal cells (MSCs) are regenerative cells that can repair injured tissue by secreting multiple paracrine factors that can immunomodulate and restore function and lung epithelial/endothelial integrity.<xref rid="sct312626-bib-0013" ref-type="ref">13</xref>, <xref rid="sct312626-bib-0014" ref-type="ref">14</xref> Numerous preclinical studies have shown that treatment with MSCs can alleviate neonatal lung injury in animal models mimicking BPD.<xref rid="sct312626-bib-0015" ref-type="ref">15</xref> Most of these rodent studies have focused on administering the cells via an intratracheal or intravenous route.<xref rid="sct312626-bib-0016" ref-type="ref">16</xref>, <xref rid="sct312626-bib-0017" ref-type="ref">17</xref>, <xref rid="sct312626-bib-0018" ref-type="ref">18</xref>, <xref rid="sct312626-bib-0019" ref-type="ref">19</xref> To date, the optimal number of administrations and route of MSC delivery to treat BPD are unknown. Therefore, the primary goal of our study was twofold: (a) determine feasibility of intranasal delivery of human umbilical cord tissue MSCs, a clinically relevant and noninvasive approach to deliver multiple doses, in neonatal rat pups, and (b) examine whether intranasal delivery of MSCs attenuates lung injury in experimental BPD.</p>
            </sec>
            <sec id="sct312626-sec-0004">
              <label>2</label>
              <title>MATERIALS AND METHODS</title>
              <sec id="sct312626-sec-0005">
                <label>2.1</label>
                <title>Cell culture and MSC preparation</title>
                <p>Umbilical cord Wharton's jelly tissue was collected from a healthy term human newborn. After tissue enzymatic digestion, cells were expanded on culture dishes under standard conditions. Wharton's jelly cells met the minimum criteria for MSCs, as described in our previous publication.<xref rid="sct312626-bib-0020" ref-type="ref">20</xref>
</p>
                <p>Preparation of MSCs was achieved as follows, 5 × 10<sup>5</sup> cells were seeded onto 100 mm tissue culture dishes and grown under standard conditions with media changes every 2‐3 days. At 24 hours prior to administration, cells were checked for confluency (80%‐90%) and the media was changed for the last time. On the day of administration, the media was removed from the dishes and the cells were washed twice with phosphate buffered saline. TrypLE Express enzyme (Thermo Fisher Scientific, Waltham, MA) was added to the dishes for 5 minutes to allow the cells to detach and an equal volume of αMEM (minimum essential medium) was added to the dishes to deactivate the TrypLE. The cell suspension was transferred to a conical tube, counted, and distributed into 20 μL aliquots containing 5 × 10<sup>5</sup> cells and phosphate buffered saline (PBS, Sigma‐Aldrich). We derived our dose based on the systematic review and meta‐analysis conducted by Augustine et al (highest standardized mean difference favoring MSC treatment for alveolarization).<xref rid="sct312626-bib-0021" ref-type="ref">21</xref> Cells were kept on ice until administration. Immediately before intranasal delivery, the cell suspension was warmed to body temperature to avoid animal stress. All cells in the experiments were seeded at passage three.</p>
              </sec>
              <sec id="sct312626-sec-0006">
                <label>2.2</label>
                <title>Animal maintenance</title>
                <p>All animal protocols were approved by The University of Texas Health Science Center (UTHSCSA) Institutional Animal Care and Use Committee. The animals received care in compliance with the <italic>Guide for the Care and Use of Laboratory Animals</italic> and experiments were carried out in compliance with the Helsinki Declaration.</p>
                <p>Timed pregnant female Sprague‐Dawley rats were obtained from Charles River Laboratories at E14‐E15 days of gestation. Animals were singly housed with 12‐hour light/dark cycles, standard rodent laboratory diet and water was provided ad libitum. Dams were provided with nesting material at E18‐E19 onwards and received DietGels (Clear H<sub>2</sub>O, Portland, ME) with cage changes (every 48 hours).</p>
                <p>On postnatal day 4, newborn rat pups were randomly assigned into four groups: (a) room air (RA), (b) BPD, (c) BPD treated with αMEM as a vehicle (BPD + Veh), and (d) BPD treated with mesenchymal stromal cells (BPD + MSCs). RA animals were survived at normoxia (21% O<sub>2</sub>) for 21 days. The remaining BPD groups were exposed to 4 days of continuous hyperoxia (60%) using a BioSpherix animal housing chamber (BioSpherix Ltd, Lacona, NY).<xref rid="sct312626-bib-0022" ref-type="ref">22</xref>, <xref rid="sct312626-bib-0023" ref-type="ref">23</xref>, <xref rid="sct312626-bib-0024" ref-type="ref">24</xref>, <xref rid="sct312626-bib-0025" ref-type="ref">25</xref> Following a moderate BPD induction, animals were housed the remainder of the 3 weeks in normoxia. Pups were marked using toe tattoos specific to each treatment group.<xref rid="sct312626-bib-0026" ref-type="ref">26</xref> BPD rats received iterative treatments of vehicle or MSCs, on days 4, 10, and 20. Body weights were measured on each treatment day. Figure <xref rid="sct312626-fig-0001" ref-type="fig">1</xref>A summarizes the experimental design.</p>
                <fig fig-type="Figure" xml:lang="en" id="sct312626-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Experimental design: A, Newborn rats were exposed to 60% O<sub>2</sub> for 4 days to induce bronchopulmonary dysplasia (BPD). BPD animals were compared to rats that were maintained in room air (RA, 21% O<sub>2</sub>). On days 4, 10, and 20, BPD treatment animals received either mesenchymal stromal cell (MSC) or vehicle (Veh). Outcomes were performed on days 20‐21. B, Schematic representation of intranasal delivery to Sprague‐Dawley rat pups. As noted, the animals were in an erect position with their necks slightly extended to facilitate delivery to the lungs</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="SCT3-9-221-g001"/>
                </fig>
              </sec>
              <sec id="sct312626-sec-0007">
                <label>2.3</label>
                <title>Intranasal delivery of MSCs or vehicle</title>
                <p>Intranasal delivery of cells or vehicle was achieved using a modified version of the methods as described by Hanson et al.<xref rid="sct312626-bib-0027" ref-type="ref">27</xref>, <xref rid="sct312626-bib-0028" ref-type="ref">28</xref> Briefly, neonatal rats were held in the nondominant hand, with the body of the animal supported by the thumb and base of the palm and the head gently immobilized between the first and second finger. For older animals, the same support was used, but the head was immobilized between the thumb under the chin and the first and second fingers just behind the ears. To encourage the treatment to travel to the lungs rather than the CNS, animals were oriented vertically, with the coronal plane perpendicular to the ground and the neck upright and extended.<xref rid="sct312626-bib-0029" ref-type="ref">29</xref> Therapies were administered using a 2‐20 μL micropipettor with extra‐long gel loading tips (Fisher Scientific, Waltham, MA) to facilitate droplet formation (refer to Figure <xref rid="sct312626-fig-0001" ref-type="fig">1</xref>B). The total instillation volume (20 μL) was administered over a 5‐minute period; this allowed for ample recovery time and aliquoted delivery to the animals.</p>
              </sec>
              <sec id="sct312626-sec-0008">
                <label>2.4</label>
                <title>Tissue processing</title>
                <p>Animals were euthanized by CO<sub>2</sub> exposure followed by thoracotomy. Carcasses were kept on ice until tissue processing was completed. Lungs were excised, and the right lung was ligated, removed, and flash frozen in liquid nitrogen for protein and RNA analysis. The left lung was inflation fixed with 4% paraformaldehyde instilled through the trachea at 20 cm pressure for 2 minutes. After 24 hours, tissues were transferred to 70% ethanol prior to histologic analysis. Lungs were cut into four levels and oriented with alternating surfaces exposed prior to creation of 5 μm paraffin embedded sections. The heart was excised and the apex flash frozen, the remaining heart tissue was fixed in 10% neutral buffered formalin. The atria of the hearts were removed, and the remaining tissue oriented such that transverse sections of the ventricles could be obtained after paraffin embedding. All histological sectioning and staining were performed by UTHSCSA's Pathology Laboratory.</p>
                <p>Lung slides were stained with hematoxylin and eosin stain, von Willebrand Factor, Masson's Trichrome, and α‐smooth muscle actin. Digital slides were created using the Aperio CS2 Digital Pathology Slide Scanner (Leica Biosystems, Wetzlar, Germany). Measurements were made using the following software: Aperio ImageScope software version 12.3.3, Pathomation (Belgium), MIPCloud (Iran), Image J, and Digimizer (Belgium).</p>
              </sec>
              <sec id="sct312626-sec-0009">
                <label>2.5</label>
                <title>Detection of human umbilical cord MSCs in rat lung tissue</title>
                <p>Five micron‐thick sections were cut from paraffin‐embedded lung tissue, deparaffinized, and stained with a monoclonal antibody specific to intact human mitochondria (MAB 1273, EMB Millipore, Burlington, VA) as described in Allard et al.<xref rid="sct312626-bib-0030" ref-type="ref">30</xref> All immunohistochemical staining was performed by the Histology and Immunohistochemistry Laboratory at UTHSCSA. Slide images were obtained at 20x magnification using Aperio slide scanning system and ImageScope software.</p>
              </sec>
              <sec id="sct312626-sec-0010">
                <label>2.6</label>
                <title>Lung morphometry</title>
                <sec id="sct312626-sec-0011">
                  <label>2.6.1</label>
                  <title>Alveolarization</title>
                  <p>To obtain a comprehensive assessment of the lungs, we measured mean linear intercepts in a total of 270 random fields (we evaluated 3 random lung sections, 30 random fields, and 3 standardized measurements per field) on each animal.</p>
                </sec>
                <sec id="sct312626-sec-0012">
                  <label>2.6.2</label>
                  <title>Alveolar tissue distribution</title>
                  <p>To discern airspace enlargement, we adapted the techniques described by Jacob et al.<xref rid="sct312626-bib-0031" ref-type="ref">31</xref> We randomly obtained 30 images per lung (10 images per 3 lung sections) that avoided major airways and vasculature. We uploaded the digital pictures onto MIPCloud for processing. The pictures covered a field of 727 μm × 482 μm, while the threshold (200) and region of interest remained constant (area spanning 235 μm × 166 μm). Supplementary Figure <xref rid="sct312626-supitem-0001" ref-type="supplementary-material">S1</xref> portrays a sample image used to calculate alveolar tissue distribution.<xref rid="sct312626-bib-0031" ref-type="ref">31</xref>
</p>
                </sec>
                <sec id="sct312626-sec-0013">
                  <label>2.6.3</label>
                  <title>Vasculogenesis</title>
                  <p>Pulmonary vessels were point counted on H&amp;E stained lung sections measuring 727 μm × 482 μm and imaged at ×20 magnification. Nine viewing lung fields were randomly created for each animal. The total number of vessels was then averaged over the number of viewing fields analyzed to generate the presented values (vessels/viewing field). Findings were confirmed by randomly choosing four animal lungs per group (save BPD + Veh) for manual counting of von Willebrand factor stained vessels. Counts were done in 20 randomly selected lung fields measuring an area of 423 μm × 530 μm at a ×20 magnification.</p>
                </sec>
                <sec id="sct312626-sec-0014">
                  <label>2.6.4</label>
                  <title>Vascular remodeling/muscularization</title>
                  <p>External diameters of pulmonary vessels ranging from 50‐200 μm were analyzed for medial wall thickness (MWT). The following equation was used to calculate MWT: ((External diameter ‐ Internal diameter) / (External diameter)) × 100.<xref rid="sct312626-bib-0032" ref-type="ref">32</xref> A total of five random pulmonary vessels per lung were analyzed in all animals. For each vessel, wall thickness was measured along the shortest length of vessel diameter. Digimizer was used to measure the medial wall thickness on digital images at ×20 magnification.</p>
                  <p>Immunostaining for α‐smooth muscle actin (α‐SMA) was used to assess pulmonary vasculature muscularization. A horizontal or vertical line was made across the shortest diameter of pulmonary vessels measuring 50‐200 μm. Thickness of the α‐SMA stained portion (along the line) was calculated over the external diameter of the vessel. All animal lungs in each group were evaluated by calculating α‐SMA thickness in five random vessels. Furthermore, positive staining for alpha‐SMA was quantified on all lungs using the Positive Pixel Count Algorithm (v9, Aperio Technologies, Inc., Vista, CA). Data are reported as positivity (number of positively stained pixels divided by the total number of pixels in the scanned image).</p>
                </sec>
                <sec id="sct312626-sec-0015">
                  <label>2.6.5</label>
                  <title>Fibrosis</title>
                  <p>Masson's trichrome staining was done to evaluate collagen deposition in the perivascular, peribronchial, and alveoli. Ten fields were observed per lung at a magnification of ×20. ImageJ was used to determine percent staining in a section measuring 2181 μm × 1446 μm.</p>
                </sec>
              </sec>
              <sec id="sct312626-sec-0016">
                <label>2.7</label>
                <title>Right ventricular hypertrophy</title>
                <p>A ratio of the thickness of the right ventricle to left ventricle+ septum on H&amp;E stains of the heart was used as an index of right ventricular hypertrophy (RVH). To measure RVH, a series of seven horizontal lines spaced at 12 μm was placed over the heart images, and the length of the septum and ventricles were calculated.</p>
              </sec>
              <sec id="sct312626-sec-0017">
                <label>2.8</label>
                <title>qRT‐PCR</title>
                <p>Total RNA was extracted from flash frozen tissue using TRIzol reagent and Phasemaker tube system (Thermo Fisher). Briefly, ~20 mg of tissue was homogenized in 1 mL of TRIzol using a beadbeater (BioSpec) for 60 seconds followed by 60 seconds rest on ice, then another 60 seconds of homogenization. The tissue homogenate was briefly spun to eliminate bubbles and transferred to the Phasemaker tubes. RNA extraction was then completed using the TRIzol manufacturer's instructions. Synthesis of cDNA was achieved using the Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Thermo Fisher) with 2 μg of RNA. qRT‐PCR reactions were created using cDNA, EasyOligo custom primers (Sigma‐Aldrich, St. Louis, MO), and SYBR Green PCR Master Mix (Thermo Fisher). The BioRad CFX384 Touch Real‐Time PCR Detection System (BioRad, Hercules, CA) was used for PCR data acquisition. The program settings were as follows: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute, followed by a melt curve (0.5°C per cycle, 60 cycles stopping at 95°C). Starting quantity of RNA was calculated in CFX Manager Software (BioRad) using the relative standard curve method and data were normalized using β‐Actin as a housekeeping gene. Primers were designed using the protocol described in Thornton and Basu 2010 and are summarized in Supplementary Table <xref rid="sct312626-supitem-0009" ref-type="supplementary-material">S1</xref>.<xref rid="sct312626-bib-0033" ref-type="ref">33</xref> Primer selection was chosen before gene array analysis, but reflect genes known to be altered in BPD, including vasculogenesis, inflammation, fibrosis, cell proliferation, and apoptosis.</p>
              </sec>
              <sec id="sct312626-sec-0018">
                <label>2.9</label>
                <title>Gene array</title>
                <p>Pathway‐specific gene expression was also analyzed using the RT2 Profiler PCR Array for Rat Endothelial Cell Biology (Qiagen, Hilden, Germany). In total, 96 genes from pathways associated with angiogenesis, vasoconstriction/vasodilation, inflammation, apoptosis, cell adhesion, coagulation, and platelet activation were profiled (for a complete listing of genes, see Supplementary Table <xref rid="sct312626-supitem-0010" ref-type="supplementary-material">S2</xref>). Clean‐up of RNA samples (n = all 24 animal lungs from the RA, BPD, and BPD + MSC group) with the RNeasy Mini Kit (Qiagen, Hilden, Germany) was performed prior to PCR profiling according to the manufacturer's instructions. Per the manufacturer's recommendation, on‐column DNA digestion was performed using the RNase‐Free DNase set (Qiagen, Hilden, Germany). RNA quality and concentration were determined using a spectrophotometer (BioTek Epoch, Winooski, VT) and cDNA was synthesized from 400 ng of total RNA using the RT2 First Strand Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RT2 Profiler reactions were then mixed, loaded into the plates, and run using the BioRad CFX384 PCR detection system according to the manufacturer's instructions. Data are reported as fold changes using the double‐delta CT formula.</p>
              </sec>
              <sec id="sct312626-sec-0019">
                <label>2.10</label>
                <title>Protein array</title>
                <p>Lung lysate was analyzed using a rat cytokine array kit (Proteome Profiler, R&amp;D Systems, Minneapolis, MN). Per manufacturer's directions, a total of 250 μg of tissue lysate was incubated in a nitrocellulose membrane array overnight at 4°C. Signals were visualized with chemiluminescence Western blot and developed on X‐ray film. The arrays were scanned, and optical densities were quantified using Image J software (NIH). The protein macroarray analysis included 79 cytokines/factors and included lung tissue protein samples from a subset of the three groups (n = all 24 animal lungs from the RA, BPD, and BPD + MSC groups).</p>
              </sec>
            </sec>
            <sec id="sct312626-sec-0020">
              <label>3</label>
              <title>STATISTICAL ANALYSIS</title>
              <p>The data generated by the described experiments was evaluated using standard statistical approaches. Continuous data were expressed as mean ± SEM. Intergroup differences for parametric data were tested with one‐way ANOVA and Tukey's comparison test and nonparametric data with Kruskall Wallis followed by Dunn's test. Data were analyzed using STATA, (version 13, College Station, TX) and a <italic>P</italic> value &lt;5% signifying statistical significance. Power analysis calculations were based on MLI differences between BPD and BPD + MSC groups in a published study demonstrating MSC efficacy in a study by Thebaud et al.<xref rid="sct312626-bib-0034" ref-type="ref">34</xref> Therefore, sample size to detect a difference, with a power of 80% and two‐sided α = .05, yielded four rats/group. We included at least eight animals per group to account for potential failure rates (ie, animal death prior to randomization into the four groups). Histologic and physiologic calculations were performed by study team members blinded to experimental groups.</p>
            </sec>
            <sec id="sct312626-sec-0021">
              <label>4</label>
              <title>RESULTS</title>
              <sec id="sct312626-sec-0022">
                <label>4.1</label>
                <title>Umbilical cord cells met minimum MSC criteria</title>
                <p>Umbilical cord Wharton's jelly‐derived cells adhered to tissue culture dishes and displayed the characteristic cell surface antigens for MSC classification (Supplementary Figure <xref rid="sct312626-supitem-0002" ref-type="supplementary-material">S2</xref>). Cells were negative for hematologic stem cell markers HLA‐DR, CD117, and CD79 alpha. Consistent with the criteria set by International Society for Cell and Gene Therapy, cells differentiated into adipocytes, chondrocytes, and osteocytes when grown with lineage specific media, as previously describe.<xref rid="sct312626-bib-0020" ref-type="ref">20</xref>
</p>
              </sec>
              <sec id="sct312626-sec-0023">
                <label>4.2</label>
                <title>Survival rate and animal growth</title>
                <p>A total of 35 animals were used in the experiments (RA n = 7, BPD n = 11, BPD + Veh n = 8, BPD + MSC n = 9). Survival rates among the groups were comparable (RA 100%, BPD 82%, and BPD + Veh = 100%, BPD + MSC 89%, log‐rank <italic>P</italic> = .6). Kaplan‐Meier curve is provided in Supplementary Figure <xref rid="sct312626-supitem-0003" ref-type="supplementary-material">S3</xref>.</p>
                <p>On postnatal day 4 mean body weight of the rat pups was 10.0 ± 0.5 g. Weight of pups increased to approximately 20 g on day 10. Growth velocity did not differ between the groups (Supplementary Figure <xref rid="sct312626-supitem-0004" ref-type="supplementary-material">S4</xref>).</p>
              </sec>
              <sec id="sct312626-sec-0024">
                <label>4.3</label>
                <title>Nasal delivery of MSCs to the lungs</title>
                <p>The pulmonary dispersion of human umbilical cord MSCs was monitored using immunohistochemistry of a human mitochondrial antibody. Supplementary Figure <xref rid="sct312626-supitem-0005" ref-type="supplementary-material">S5</xref> provides evidence that intranasal administration of MSCs, at a dose of 5 × 10<sup>5</sup>, migrated towards the rat lungs.</p>
              </sec>
              <sec id="sct312626-sec-0025">
                <label>4.4</label>
                <title>Intranasal delivery of MSCs restore lung alveolarization</title>
                <p>Exposure of hyperoxia created the characteristic histologic findings in human BPD. Figure <xref rid="sct312626-fig-0002" ref-type="fig">2</xref> show representative light microscopic photographs of histological H&amp;E stain differences between the groups. Specifically, animals that received 4 days of 60% O<sub>2</sub> had fewer and larger sized alveoli, indicative of arrested alveolar development. Intranasal delivery of MSCs improved alveolarization, as measured by mean linear intercept (BPD 64.3 ± 2.6 μm vs BPD + MSC 57.3 ± 1.5 μm, <italic>P</italic> &lt; .01) and alveolar tissue distribution. No difference was found comparing mean linear intercept in RA and BPD + MSC groups or BPD with BPD + Veh (<italic>P</italic> = .64 and .11, respectively).</p>
                <fig fig-type="Figure" xml:lang="en" id="sct312626-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Intranasal delivery of mesenchymal stromal cells (MSCs) restores lung alveolarization. Hematoxylin and eosin stained lung sections show the characteristic simplification of lung alveolarization (larger, but fewer airspaces) in the hyperoxic injured bronchopulmonary dysplasia group (BPD). Using mean linear intercept as a surrogate for lung alveolar growth, intranasal delivery of MSCs fully restored lung architecture. Findings from alveolar tissue distribution corroborate histologic and mean linear intercept findings. Measurements expressed as mean ± SEM and included all 32 animals. RA, room air; Veh, vehicle. Mean linear intercepts: *<italic>P</italic> &lt; .05 compared to BPD and BPD + Veh; °<italic>P</italic> &gt; .05 compared to RA. Scale bar = 100 μm. Alveolar tissue distribution: *<italic>P</italic> &lt; .05 compared to BPD and BPD + Veh, °<italic>P</italic> &lt; .05 compared to RA</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="SCT3-9-221-g002"/>
                </fig>
              </sec>
              <sec id="sct312626-sec-0026">
                <label>4.5</label>
                <title>Vascular development improved with MSCs given via the intranasal route</title>
                <p>To assess the effects of hyperoxic injury on vasculature development, the number of pulmonary vessels were counted on H&amp;E stained lung sections (Figure <xref rid="sct312626-fig-0003" ref-type="fig">3</xref>A). Although significance was not obtained (<italic>P</italic> = .07), the pattern suggests that compared to RA rats, hyperoxic exposed animals trended towards a reduction in the number of blood vessels (1.4 ± 0.3 vs 1.7 ± 0.3 blood vessels/field, respectively, <italic>P</italic> = .07), whereas treatment with MSCs restored vessel number (1.9 ± 0.2 blood vessels/field).</p>
                <fig fig-type="Figure" xml:lang="en" id="sct312626-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Intranasal delivery of mesenchymal stromal cells (MSCs) improves lung vascularization. A, Hematoxylin and eosin stained lung sections show a trend towards a decreased number of blood vessels in the hyperoxic injured bronchopulmonary dysplasia group (BPD). MSC therapy tended to have a higher blood vessel number. Measurements expressed as mean ± SEM and included all animals. Black arrows depict pulmonary vessels. Veh, vehicle. Scale bar = 100 μm, magnification at ×20. B, Von Willebrand Factor staining (magenta) of room air control animals (RA), BPD, and BPD + MSC depict pulmonary vascular development was restored after intranasal stem cell treatment. *<italic>P</italic> &lt; .05 compared to BPD. Scale bar = 100 μm</p>
                  </caption>
                  <graphic id="nlm-graphic-7" xlink:href="SCT3-9-221-g003"/>
                </fig>
                <p>To confirm the above findings, von Willebrand factor staining was conducted in the following cohorts: RA, BPD, and BPD + MSC animals. Similar to H&amp;E results, hyperoxia‐induced BPD animals demonstrated a lower number of blood vessels when compared with RA animals (6.2 ± 1.3 vs 7.5 ± 1.4, <italic>P</italic> &lt; .01; Figure <xref rid="sct312626-fig-0003" ref-type="fig">3</xref>B). Blood vessel number was restored in the BPD animals treated with MSCs (7.8 ± 1.3, <italic>P</italic> &lt; .01compared to BPD; <italic>P</italic> = .5 compared to RA).</p>
              </sec>
              <sec id="sct312626-sec-0027">
                <label>4.6</label>
                <title>Smooth muscle thickening was attenuated with MSC and CdM therapy</title>
                <p>To determine the effects of MSCs on pulmonary vascular remodeling, medial wall thickness (MWT) was determined in H&amp;E lung sections. MWT was elevated in BPD and BPD + Veh animals (69.9% ± 7.1% and 64.3% ± 8.0%, respectively, Figure <xref rid="sct312626-fig-0004" ref-type="fig">4</xref>). MSC and CdM therapy significantly decreased MWT when compared to the BPD group.</p>
                <fig fig-type="Figure" xml:lang="en" id="sct312626-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <p>Intranasal delivery of mesenchymal stromal cells (MSCs) prevented early stages of pulmonary vascular remodeling in peripheral vessels. Hyperoxia‐exposed rats (BPD) had a significant increase in medial wall thickness in pulmonary vessels measuring &lt;100 μm when compared to room air control animals (RA). Medial wall thickness in the BPD animals exposed to MSC therapy returned the levels to baseline. Measurements expressed as mean ± SEM in five random pulmonary vessels per lung in all animals. *<italic>P</italic> &lt; .05 compared to BPD and BPD + Veh. Scale bar = 20 μm, magnification of hematoxylin and eosin images at ×80</p>
                  </caption>
                  <graphic id="nlm-graphic-9" xlink:href="SCT3-9-221-g004"/>
                </fig>
              </sec>
              <sec id="sct312626-sec-0028">
                <label>4.7</label>
                <title>Pulmonary vessel muscularization and cardiac remodeling was not elicited in our model</title>
                <p>Vessel muscularization did not differ among the groups (Supplementary Figure <xref rid="sct312626-supitem-0006" ref-type="supplementary-material">S6</xref>) and cardiac RVH was not produced in any of the BPD groups (Supplementary Figure <xref rid="sct312626-supitem-0006" ref-type="supplementary-material">S6</xref>).</p>
              </sec>
              <sec id="sct312626-sec-0029">
                <label>4.8</label>
                <title>Lung fibrosis was similar among groups</title>
                <p>Although collagen staining was seen in the peribronchial areas, it was not appreciable in the interstitium (data not shown).</p>
              </sec>
              <sec id="sct312626-sec-0030">
                <label>4.9</label>
                <title>VEGF mRNA lung expression increased after MSC treatment</title>
                <p>MSC treatment increased vascular endothelial growth factor (VEGF) mRNA expression in lung homogenates compared to RA rats but did not differ from the BPD animals (Supplementary Figure <xref rid="sct312626-supitem-0007" ref-type="supplementary-material">S7</xref>). RNA levels of bax, caspase 3, interleukin‐6, interleukin‐10, timp 2, and transforming growth factor‐β were not affected by hyperoxia or MSC treatment.</p>
              </sec>
              <sec id="sct312626-sec-0031">
                <label>4.10</label>
                <title>Differential expression of genes between RA, BPD, and BPD + MSC animals</title>
                <p>To identify the effect of MSCs on lung repair and restoration, differences in the mRNA levels of genes were examined using a PCR array and compared BPD + MSC to BPD and RA. We found that MSCs had an effect (≥twofold difference) in the expression profile of two genes: <italic>Anxa5</italic> (cell signaling, vesicle trafficking, cell division/migration, and apoptosis) and <italic>NPPB</italic> (cardiac remodeling, vasculogenesis, antimicrobial) (refer to Figure <xref rid="sct312626-fig-0005" ref-type="fig">5</xref>A).<xref rid="sct312626-bib-0035" ref-type="ref">35</xref>, <xref rid="sct312626-bib-0036" ref-type="ref">36</xref>
</p>
                <fig fig-type="Figure" xml:lang="en" id="sct312626-fig-0005" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <p>PCR gene array data demonstrates mesenchymal stromal cell (MSC) treatment in animals with hyperoxic lung injury influences biological processes, cellular components, and molecular function. A, A comparison analysis of gene expression was performed using the RT2 Profiler PCR Array for Rat Endothelial Cell Biology between the following animal groups: room air (RA) control, hyperoxia‐induced bronchopulmonary dysplasia (BPD), and BPD treated with MSCs (BPD + MSC). RNA was analyzed from rat lung tissue on day 20‐21 and included all animal lungs. Using a threshold of twofold expression change and statistical significance of <italic>P</italic> &lt; .05, two separate genes were identified among the 3 groups. B, Genes differentially expressed in RA control animals compared to animals exposed to hyperoxia‐induced BPD and treated with MSCs</p>
                  </caption>
                  <graphic id="nlm-graphic-11" xlink:href="SCT3-9-221-g005"/>
                </fig>
              </sec>
              <sec id="sct312626-sec-0032">
                <label>4.11</label>
                <title>MSCs express proteins that modulate inflammation, cell survival, and wound healing</title>
                <p>To investigate the effects of MSCs on lung protein expression we performed a protein macroarray. Of the 79 factors/cytokines tested, RA only expressed 30 proteins while BPD and BPD + MSC expressed 61 and 58 proteins, respectively. When compared to RA and BPD + MSC, BPD had four elevated proteins: CX3CL1, TNFα, TIM‐1, and RGM‐A. On the other hand, when compared to RA and BPD, MSCs showed an enriched expression of G‐CSF, WISP‐1, and prolactin. The lungs of MSC treated mice had significantly lower levels of BPD injury related to proteins associated with immunomodulation (CX3CL1, TNFα, TIM‐1, hepassocin, neprilysin), cell survival (osteoprotegerin), and wound healing (MMP‐2, LIF). Although proteins pertaining to fibrogenesis and anti‐vascular processes were different between RA and BPD + MSC groups, there was no significant difference between the BPD and BPD + MSC groups. The single protein that demonstrated a difference between the BPD and BPD + MSC group (post hoc analysis) was G‐CSF (<italic>P</italic> = .011). MSC treatment in this experimental model of BPD appears to impact inflammation when the genes were grouped into six processes (pro‐inflammation, anti‐inflammation, cell survival, wound healing, fibrogenesis, and anti‐vascular). Figure <xref rid="sct312626-fig-0006" ref-type="fig">6</xref> summarizes the top proteins per functional category and sample protein membranes are found in Supplementary Figure <xref rid="sct312626-supitem-0008" ref-type="supplementary-material">S8</xref>. Supplementary Figure <xref rid="sct312626-supitem-0008" ref-type="supplementary-material">S8</xref> also describes the statistical computation for the six processes and Supplementary Table <xref rid="sct312626-supitem-0012" ref-type="supplementary-material">S4</xref> provides references for the groupings.</p>
                <fig fig-type="Figure" xml:lang="en" id="sct312626-fig-0006" orientation="portrait" position="float">
                  <label>Figure 6</label>
                  <caption>
                    <p>Protein analysis of lung homogenates from room air (RA) control, oxygen injured (bronchopulmonary dysplasia [BPD]), and BPD treated with mesenchymal stromal cells (BPD + MSCs). A, Select data displayed in the following grouping: Pro‐inflammatory; Anti‐inflammatory; Cell survival; Wound healing; Fibrogenesis; and Anti‐vascular. Data presented as mean ± SEM. N, all animals in each group. *<italic>P</italic> &lt; .05 compared to BPD. CX3CL1, C‐X3‐C motif chemokine ligand 1; G‐CSF, granulocyte colony stimulating factor; IGFBP, insulin like growth factor binding protein; IL, interleukin; LIF, leukemia inhibitory factor; LIX, C‐X‐C motif chemokine 5; MMP, matrix metalloproteinase; PDGF‐BB, platelet derived growth factor receptor beta; Pref, preadipocyte factor; RGM‐A, repulsive guidance molecule BMP co‐receptor A; TIM, T‐cell immunoglobulin mucin receptor; TNF, tumor necrosis; TWEAK, TNF receptor superfamily member 12A; WISP, WNT1 inducible signaling pathway. B, Mean scores for the cytokines within their respective pathway. Of note, the RA group had multiple pathway differences compared to the other groups. However, only the anti‐inflammatory cytokines yielded significant between the BPD and BPMSC. The groups were examined using ANOVA, followed by pairwise comparisons using Bonferroni's adjusted significance level, where <italic>P</italic> &lt; .05 was deemed significant</p>
                  </caption>
                  <graphic id="nlm-graphic-13" xlink:href="SCT3-9-221-g006"/>
                </fig>
              </sec>
            </sec>
            <sec id="sct312626-sec-0033">
              <label>5</label>
              <title>DISCUSSION</title>
              <p>The major findings of the present study are that human umbilical cord tissue MSCs given: (a) intranasally is feasible and a noninvasive approach for delivery to the lungs, (b) can potentially restore lung alveolarization and vascularization in a moderate model of BPD, and (c) the restorative effects may, in part, be due to a concerted effort on angiogenesis, immunomodulation, wound healing, and cell survival.</p>
              <p>The rationale for using MSCs as novel agents for BPD is based on their ability to secrete factors that contribute to tissue repair. MSCs are known to stimulate blood vessel formation, blunt inflammation, and promote alveolar epithelial cell survival and proliferation. While most preclinical BPD studies report the therapeutic action of these cells in BPD using an intratracheal and intravenous route, our project is the first to report intranasal delivery is a viable and efficacious approach (Supplementary Table <xref rid="sct312626-supitem-0011" ref-type="supplementary-material">S3</xref>). Previous reports by De Paepe et al attempted the intranasal route of stromal cells for BPD but found either no obvious pulmonary effect or worsening in lung development.<xref rid="sct312626-bib-0037" ref-type="ref">37</xref>, <xref rid="sct312626-bib-0038" ref-type="ref">38</xref> Conversely, a study in mice with ovalbumin‐induced asthma similarly demonstrated abrogation of airway injury after intranasal administration of MSCs.<xref rid="sct312626-bib-0039" ref-type="ref">39</xref> Additionally, these investigators demonstrated that intranasal delivery was more successful in reducing lung fibrosis, inflammation, and airway reactivity than the intravenous route.</p>
              <p>Reasons that may explain the effectiveness in our study include: multiple dose administration, less severe BPD model, intranasal volume given, and anatomic positioning of animals during cell delivery.<xref rid="sct312626-bib-0040" ref-type="ref">40</xref>, <xref rid="sct312626-bib-0041" ref-type="ref">41</xref>, <xref rid="sct312626-bib-0042" ref-type="ref">42</xref> Moreover, using an automated cell counter we tested the viability of the human umbilical cord MSCs just prior to animal administration and our yield ranged between 93% and 99%.<xref rid="sct312626-bib-0020" ref-type="ref">20</xref> Despite being a crude approximation of cell viability, we wanted a quick and objective measure of the percent of live cells we were providing to the animals. Prior studies administering MSCs intranasally for lung disease do not mention stromal cell viability before animal delivery.</p>
              <p>Intranasal administration of MSCs is a translationally relevant mode of administration that is noninvasive, rapidly absorbed, and offers a tremendous option for frequent dosing.<xref rid="sct312626-bib-0043" ref-type="ref">43</xref> Clinical advantages of the intranasal route include the ease of administration, whereby a patient does not require an intravenous line or endotracheal tube. Furthermore, intranasal delivery of products avoids the initial intestinal metabolism observed in intravenous, oral, or subcutaneous routes. The intranasal delivery of cells/drugs can also provide systemic effects, as the nasal mucosa is a highly vascularized tissue. In a study by Balyasnikova et al, intranasal delivery of labeled MSCs showed a high quantity of cells penetrating the lung parenchyma.<xref rid="sct312626-bib-0044" ref-type="ref">44</xref> These findings are opposite of those found by Reitz et al whereby neural stem/progenitor cells given intranasally to mice migrated to the brain and spleen but were not visualized in the lungs.<xref rid="sct312626-bib-0045" ref-type="ref">45</xref>
</p>
              <p>Our study is in line with the literature showing that MSCs improve alveolarization and vascularization in animal models of BPD.<xref rid="sct312626-bib-0019" ref-type="ref">19</xref>, <xref rid="sct312626-bib-0034" ref-type="ref">34</xref>, <xref rid="sct312626-bib-0046" ref-type="ref">46</xref> Other investigators have established improved survival, animal growth, and exercise tolerance after MSC treatment.<xref rid="sct312626-bib-0019" ref-type="ref">19</xref>, <xref rid="sct312626-bib-0034" ref-type="ref">34</xref> We attribute the lack of these findings to the decreased severity of BPD in our animals. Our group chose to limit the injury model to the saccular stage (first four days in rodents) of lung development, as we believe this replicates the alveolar simplification and dysmorphic pulmonary vessel development observed in clinical practice (“new BPD”).<xref rid="sct312626-bib-0003" ref-type="ref">3</xref> This assumption is further strengthened by the fact that our model did not elicit late findings of pulmonary vascular remodeling (muscularization and RVH). These late findings of pulmonary vascular remodeling are observed in ~10% of neonates with severe BPD.<xref rid="sct312626-bib-0047" ref-type="ref">47</xref>, <xref rid="sct312626-bib-0048" ref-type="ref">48</xref> We also did not appreciate the lung fibrosis characteristic in other studies that induced BPD with higher oxygen levels and longer duration of the injury.<xref rid="sct312626-bib-0049" ref-type="ref">49</xref>, <xref rid="sct312626-bib-0050" ref-type="ref">50</xref>, <xref rid="sct312626-bib-0051" ref-type="ref">51</xref>
</p>
              <p>Our gene data emphasizes the key roles angiogenesis and cell membrane repair mechanisms have on proper lung development. MSCs increased the expression of NPPB, a neovasculatory factor that stimulates endothelial regeneration.<xref rid="sct312626-bib-0036" ref-type="ref">36</xref>, <xref rid="sct312626-bib-0052" ref-type="ref">52</xref> The neovascular effects of NPPB are secondary to endothelial cell proliferation, migration, and recruitment of bone‐marrow derived endothelial progenitor cells.<xref rid="sct312626-bib-0036" ref-type="ref">36</xref>, <xref rid="sct312626-bib-0052" ref-type="ref">52</xref> Studies have clearly demonstrated the important role of the vascular endothelium during lung epithelial cell proliferation and maturation.<xref rid="sct312626-bib-0053" ref-type="ref">53</xref>
</p>
              <p>A premature neonate is exposed to hyperoxia and ventilator‐associated trauma contributing to an impairment in the alveolar epithelial barrier. Normally, for cells to survive there must be a quick ability to reseal the membrane and restore epithelial barrier structure and function. However, this may be altered under chronic injury (eg, hyperoxia). For appropriate membrane repair, a series of steps must occur including an influx of calcium, activation of vesicular exocytosis, and upregulation of annexin production.<xref rid="sct312626-bib-0054" ref-type="ref">54</xref> Annexins act as environmental sensors that signal cell adaptation to stress, that are highly abundant in endothelial cells and have been implicated in in human airway epithelial cell membrane repair mechanisms.<xref rid="sct312626-bib-0035" ref-type="ref">35</xref>, <xref rid="sct312626-bib-0055" ref-type="ref">55</xref>, <xref rid="sct312626-bib-0056" ref-type="ref">56</xref>, <xref rid="sct312626-bib-0057" ref-type="ref">57</xref> This study demonstrated an increase in <italic>anxa5</italic> gene production in BPD animals treated with MSCs.</p>
              <p>The immunomodulatory properties of MSCs make them novel and invaluable agents for the repair of lungs injured by chronic inflammation. Studies propose MSCs subdue immunologic responses by secreting soluble factors known to be immunosuppressive.<xref rid="sct312626-bib-0058" ref-type="ref">58</xref>, <xref rid="sct312626-bib-0059" ref-type="ref">59</xref>, <xref rid="sct312626-bib-0060" ref-type="ref">60</xref>, <xref rid="sct312626-bib-0061" ref-type="ref">61</xref> In our study, protein analysis of animals with hyperoxic lung injury treated with MSCs reduced the production of the pro‐inflammatory cytokines TNFα, CX3CL1, and TIM‐1. A growing number of translational studies support MSCs can regulate TNF signaling in BPD.<xref rid="sct312626-bib-0062" ref-type="ref">62</xref>, <xref rid="sct312626-bib-0063" ref-type="ref">63</xref> In a study examining the effects of human umbilical cord MSC microvesicles in renal injury, MSC microvesicles decreased inflammation through the downregulation of TNFα and CX3CL1.<xref rid="sct312626-bib-0064" ref-type="ref">64</xref> Additionally, the anti‐inflammatory roles of hepassocin and G‐CSF, found higher in our BPD + MSC cohort, have been the subject of recent studies.<xref rid="sct312626-bib-0065" ref-type="ref">65</xref>, <xref rid="sct312626-bib-0066" ref-type="ref">66</xref> Our stem cell treated animals had increased levels of lung neprilysin, a known factor that influences not only immune modulation but also pulmonary vascular growth.<xref rid="sct312626-bib-0067" ref-type="ref">67</xref> The upward trend in TGF‐β1 after MSC administration abrogates the activation of T cells and natural killer cells.<xref rid="sct312626-bib-0061" ref-type="ref">61</xref>, <xref rid="sct312626-bib-0063" ref-type="ref">63</xref> We were unable to replicate findings that have shown MSCs can increase the expression of IL‐6 (anti‐apoptotic) and IL‐10 (anti‐inflammatory) to reduce lung injury.<xref rid="sct312626-bib-0068" ref-type="ref">68</xref>
</p>
              <p>Wound healing is a multifaceted process that requires a balanced response between re‐epithelialization, inflammation, and tissue granulation. After tissue injury, epithelial cells rapidly begin repairing the wound via secretion of MMPs and LIF.<xref rid="sct312626-bib-0069" ref-type="ref">69</xref>, <xref rid="sct312626-bib-0070" ref-type="ref">70</xref>, <xref rid="sct312626-bib-0071" ref-type="ref">71</xref>, <xref rid="sct312626-bib-0072" ref-type="ref">72</xref> During the inflammatory phase, platelets are recruited to curtail blood loss and macrophages and neutrophils migrate to the wound to remove debris. The extracellular matrix strengthens the initial clot and initiates scar formation.<xref rid="sct312626-bib-0073" ref-type="ref">73</xref> The final stage of healing focuses on remodeling the scar and regaining normal tissue function. These dynamic processes describes the tissue remodeling (Galectin‐1, Fibulin 3) seen in our study.<xref rid="sct312626-bib-0074" ref-type="ref">74</xref>, <xref rid="sct312626-bib-0075" ref-type="ref">75</xref> The protein microarray of rat lung homogenates with BPD also demonstrated cell survival properties after MSC delivery. For example, osteoprotegerin and WISP‐1 support cell survival in TNF‐induced apoptotic events and while prolactin is known for its role in reproductive functions it is also contains anti‐apoptotic properties.<xref rid="sct312626-bib-0076" ref-type="ref">76</xref>, <xref rid="sct312626-bib-0077" ref-type="ref">77</xref>, <xref rid="sct312626-bib-0078" ref-type="ref">78</xref>, <xref rid="sct312626-bib-0079" ref-type="ref">79</xref>
</p>
              <p>Intranasal delivery of therapeutic agents may represent a less invasive strategy for treating critically ill neonates. Relatively few studies have investigated the efficacy of intranasal administration of therapeutic agents for lung disease, and to our knowledge none of the current literature has investigated the use of intranasally delivered human umbilical cord Wharton's jelly tissue MSCs for BPD. The current study suggests that intranasally delivered MSCs may represent a promising regenerative therapy for treating chronic lung disease in preterm neonates. However, as with all studies the current work should be interpreted with considerations for the limitations of the study. First, although the rodent model is well established and provides valuable insight into the pathophysiology of BPD, it is not a premature model and therefore does not represent the full milieu of illness experienced by preterm neonates. In retrospect, we also would have added a cohort of RA animals that received MSCs. In this way, we could have further demonstrated safety. Given the heightened production of numerous proteins following MSC therapy brings into question whether we needed to provide three intranasal doses. We cannot exclude that these results are a consequence of examining the proteomic expression 1 day after the last administration. Given the pleotropic effects of many of these cytokines another drawback is that the biologic processes we assigned may oversimplify their role/action in the body. Similar to intravenous and intratracheal routes, administering one dose of intranasal MSCs may suffice and may not imbalance or produce factors that when secreted chronically may potentially be harmful. In the future, our experiments will incorporate the efficacy of intranasal MSCs in a severe model of BPD and assess pulmonary function testing, fibrosis, and animal survival. Furthermore, we also plan to examine for MSC infiltration in other tissues including the brain, spleen, kidneys, and heart. These studies will be furthered by considering potential strategies to optimize or improve the proposed route of administration, such as: the timing and frequency of cell‐based or cell‐free therapies and the standardization of the regenerative preparation.</p>
            </sec>
            <sec id="sct312626-sec-0034">
              <label>6</label>
              <title>CONCLUSION</title>
              <p>In summary, we provide evidence that the intranasal route of human umbilical cord tissue MSC delivery for BPD is effective in restoring lung alveolar growth and vascular development. Importantly, this study demonstrates that this noninvasive route of cell‐based administration may be given separately or as an adjunct/alternate to other routes. Our findings are translationally notable, given that premature neonates who develop BPD may no longer be intubated (but on noninvasive respiratory modes) nor require intravenous access (on full enteral volume). Ultimately, further studies will be necessary, however, this approach can theoretically be tested in other models of rodent lung injury.</p>
            </sec>
            <sec sec-type="COI-statement" id="sct312626-sec-0037">
              <title>CONFLICT OF INTEREST</title>
              <p>The authors indicated no potential conflicts of interest.</p>
            </sec>
            <sec id="sct312626-sec-0036">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>A.M.: conception and design, financial support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of the manuscript; C.W. and L.W.: conception and design, data analysis and interpretation, manuscript writing; J.J.: collection and/or assembly of data, final approval of the manuscript; M.J., M.N., K.Q., A.C., and T.S.: collection and/or assembly of data; M.P.: collection and/or assembly of data, illustrations; Y.A.: manuscript writing; S.M.: collection and/or assembly of data, data analysis and interpretation; P.H.: conception and design, manuscript writing, final approval of the manuscript; S.A.: data analysis and interpretation, final approval of the manuscript.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0001">
                <caption>
                  <p><bold>Supplementary Figure 1: Sample method used to calculate Alveolar Tissue Distribution.</bold> Using MIPCloud hematoxylin and eosin lung sections were uploaded and standardized thresholds (200) and region of interest were obtained. The program computes the phasefraction (ie, alveolar tissue distribution). Scale bar = 100 μm.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s001.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0002">
                <caption>
                  <p><bold>Supplementary Figure 2: Human umbilical cord cells met minimum mesenchymal stromal cell (MSC) criteria.</bold> Umbilical cord cells had the characteristic fibroblast‐like morphology and adhered to plastic under standard culture conditions and expressed (magenta) specific cell surface antigen markers CD73, CD 90, and CD 105, while negative controls are seen in grey. Scale bar = 40 μm.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s002.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0003">
                <caption>
                  <p><bold>Supplementary Figure 3: Kaplan‐Meier survival curve.</bold> Survival outcomes between the 4 groups did not demonstrate statistical differences. RA = room air; BPD = bronchopulmonary dysplasia; Veh = vehicle, MSC = mesenchymal stromal cell.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s003.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0004">
                <caption>
                  <p><bold>Supplementary Figure 4: Body weight curve showed no difference among groups.</bold> RA = room air; BPD = bronchopulmonary dysplasia; Veh = vehicle, MSC = mesenchymal stromal cell.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s004.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0005">
                <caption>
                  <p><bold>Supplementary Figure 5: Xenotransplantation of human umbilical cord MSCs via the nasal route migrated to the lungs in rats with hyperoxic injury.</bold> Immunohistochemistry of rat lung sections stained for human mitochondrial antibody (brown, pointed by black arrows). Depicted are lung sections for 5 randomly chosen animals in the BPD + MSC cohort. Bars denote 50 μm.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s005.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0006">
                <caption>
                  <p><bold>Supplementary Figure 6: Alpha smooth muscle actin (SMA) staining of pulmonary blood vessels and hematoxylin stained hearts.</bold> No difference noted between the groups in pulmonary vessel muscularization nor right ventricle remodeling; n = all animals/group. RA = room air control; BPD = bronchopulmonary dysplasia; BPD + MSC = bronchopulmonary dysplasia treated with mesenchymal stomal cells. Scale bar for SMA = 10 μm and heart sections = 200 μm.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s006.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0007">
                <caption>
                  <p><bold>Supplementary Figure 7: RT‐PCR data of rat lung homogenates.</bold> IL‐interleukin, TIMP‐tissue inhibitors of metalloproteinases, TGF‐transforming growth factor, VEGF‐vascular endothelial growth factor. Data are shown as median with IQR. RA = room air control; BPD = bronchopulmonary dysplasia; BPD + MSC = bronchopulmonary dysplasia treated with mesenchymal stomal cells. N = all animals/group. * <italic>P</italic> &lt; 0.05 compared to RA.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s007.zip">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0008">
                <caption>
                  <p><bold>Supplementary Figure 8: Sample protein array membranes for room air (RA) control, hyperoxia‐induced lung injury (BPD), and BPD animals treated with mesenchymal stromal cells (BPD + MSCs).</bold> (A) blots (B) all plots (C) statistical methodology for processes. Labels below were taken from vendor (R&amp;D) pamphlet.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s008.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0009">
                <caption>
                  <p><bold>Supplementary Table 1 List of forward and reverse RNA primers. BAX = BCL2 associated x;</bold> Casp = caspase; IL = interleukin; TIMP = tissue inhibitor of metalloproteinases; VEGF = vascular endothelial growth factor; TGF = transforming growth factor.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s009.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0010">
                <caption>
                  <p><bold>Supplementary Table 2</bold> List of genes tested in the RT2 Profiler PCR Array for Rat Endothelial Cell Biology.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s010.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0011">
                <caption>
                  <p><bold>Supplementary Table 3</bold> Advantages/disadvantages of the intranasal route for delivery of human umbilical cord mesenchymal stromal cells.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s011.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="sct312626-supitem-0012">
                <caption>
                  <p><bold>Supplementary Table 4</bold> References for groups of biologic processes.</p>
                </caption>
                <media xlink:href="SCT3-9-221-s012.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="sct312626-sec-0035">
              <title>ACKNOWLEDGMENTS</title>
              <p>Data were generated in the Flow Cytometry Shared Resource Facility, which is supported by UTHSCSA, NIH‐NCI P30 CA054174‐20 (Cancer Therapy and Research Center at UTHSCSA) and UL1 TR001129 (Clinical and Translational Science Award. We would also like to thank the Pathology Core at UTHSCSA. The study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR001118; UTHSCSA School of Medicine Clinical Investigator Kickstart Pilot Grant; and Francis Family Foundation.</p>
            </ack>
            <sec sec-type="data-availability" id="sct312626-sec-0039">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
            </sec>
            <ref-list id="sct312626-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="sct312626-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0001"><string-name><surname>Johnson</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Patel</surname><given-names>AL</given-names></string-name>, <string-name><surname>Jegier</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Engstrom</surname><given-names>JL</given-names></string-name>, <string-name><surname>Meier</surname><given-names>PP</given-names></string-name>. <article-title>Cost of morbidities in very low birth weight infants</article-title>. <source xml:lang="en">J Pediatr</source>. <year>2013</year>;<volume>162</volume>:<fpage>243</fpage>‐<lpage>249.e1</lpage>.<pub-id pub-id-type="pmid">22910099</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="miscellaneous" id="sct312626-cit-0002"><string-name><surname>Martin</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>BE</given-names></string-name>, <string-name><surname>Osterman</surname><given-names>MJK</given-names></string-name>, et al. National Vital Statistics Reports Volume 64, Number 1, January 15, <year>2015</year>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0003"><string-name><surname>Jobe</surname><given-names>AH</given-names></string-name>. <article-title>The new bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Curr Opin Pediatr</source>. <year>2011</year>;<volume>23</volume>:<fpage>167</fpage>‐<lpage>172</lpage>.<pub-id pub-id-type="pmid">21169836</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0004"><string-name><surname>Digeronimo</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Mustafa</surname><given-names>SB</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>RM</given-names></string-name>, et al. <article-title>Mechanical ventilation down‐regulates surfactant protein a and keratinocyte growth factor expression in premature rabbits</article-title>. <source xml:lang="en">Pediatr Res</source>. <year>2007</year>;<volume>62</volume>:<fpage>277</fpage>‐<lpage>282</lpage>.<pub-id pub-id-type="pmid">17622950</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0005"><string-name><surname>Doyle</surname><given-names>LW</given-names></string-name>. <article-title>Cardiopulmonary outcomes of extreme prematurity</article-title>. <source xml:lang="en">Semin Perinatol</source>. <year>2008</year>;<volume>32</volume>:<fpage>28</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">18249237</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0006"><string-name><surname>Islam</surname><given-names>JY</given-names></string-name>, <string-name><surname>Keller</surname><given-names>RL</given-names></string-name>, <string-name><surname>Aschner</surname><given-names>JL</given-names></string-name>, <string-name><surname>Hartert</surname><given-names>TV</given-names></string-name>, <string-name><surname>Moore</surname><given-names>PE</given-names></string-name>. <article-title>Understanding the short‐ and long‐term respiratory outcomes of prematurity and bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2015</year>;<volume>192</volume>:<fpage>134</fpage>‐<lpage>156</lpage>.<pub-id pub-id-type="pmid">26038806</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0007"><string-name><surname>Schmidt</surname><given-names>B</given-names></string-name>, <string-name><surname>Asztalos</surname><given-names>EV</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>RS</given-names></string-name>, et al. <article-title>Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low‐birth‐weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms</article-title>. <source xml:lang="en">JAMA</source>. <year>2003</year>;<volume>289</volume>:<fpage>1124</fpage>‐<lpage>1129</lpage>.<pub-id pub-id-type="pmid">12622582</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0008"><string-name><surname>Collins</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Tibboel</surname><given-names>D</given-names></string-name>, <string-name><surname>de Kleer</surname><given-names>IM</given-names></string-name>, et al. <article-title>The future of bronchopulmonary dysplasia: emerging pathophysiological concepts and potential new avenues of treatment</article-title>. <source xml:lang="en">Front Med</source>. <year>2017</year>;<volume>4</volume>:<fpage>61</fpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0009"><string-name><surname>Coalson</surname><given-names>JJ</given-names></string-name>. <article-title>Pathology of new bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Semin Neonatol</source>. <year>2003</year>;<volume>8</volume>:<fpage>73</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">12667832</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0010"><string-name><surname>Chess</surname><given-names>PR</given-names></string-name>, <string-name><surname>D'Angio</surname><given-names>CT</given-names></string-name>, <string-name><surname>Pryhuber</surname><given-names>GS</given-names></string-name>, <string-name><surname>Maniscalco</surname><given-names>WM</given-names></string-name>. <article-title>Pathogenesis of bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Semin Perinatol</source>. <year>2006</year>;<volume>30</volume>:<fpage>171</fpage>‐<lpage>178</lpage>.<pub-id pub-id-type="pmid">16860156</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0011"><string-name><surname>Mason</surname><given-names>C</given-names></string-name>, <string-name><surname>Dunnill</surname><given-names>P</given-names></string-name>. <article-title>A brief definition of regenerative medicine</article-title>. <source xml:lang="en">Regen Med</source>. <year>2008</year>;<volume>3</volume>:<fpage>1</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">18154457</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0012"><string-name><surname>Hunziker</surname><given-names>R</given-names></string-name>. <article-title>Regenerative medicine—fact sheet</article-title>. <source xml:lang="en">Natl Inst Health</source>. <year>2010</year>;<fpage>1</fpage>‐<lpage>2</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0013"><string-name><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name><surname>Su</surname><given-names>X</given-names></string-name>, <string-name><surname>Popov</surname><given-names>B</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JW</given-names></string-name>, <string-name><surname>Serikov</surname><given-names>V</given-names></string-name>, <string-name><surname>Matthay</surname><given-names>MA</given-names></string-name>. <article-title>Intrapulmonary delivery of bone marrow‐derived mesenchymal stem cells improves survival and attenuates endotoxin‐induced acute lung injury in mice</article-title>. <source xml:lang="en">J Immunol</source>. <year>2007</year>;<volume>179</volume>:<fpage>1855</fpage>‐<lpage>1863</lpage>.<pub-id pub-id-type="pmid">17641052</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0014"><string-name><surname>Fang</surname><given-names>X</given-names></string-name>, <string-name><surname>Neyrinck</surname><given-names>AP</given-names></string-name>, <string-name><surname>Matthay</surname><given-names>MA</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JW</given-names></string-name>. <article-title>Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin‐1</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2010</year>;<volume>285</volume>:<fpage>26211</fpage>‐<lpage>26222</lpage>.<pub-id pub-id-type="pmid">20554518</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0015"><string-name><surname>Bernardo</surname><given-names>ME</given-names></string-name>, <string-name><surname>Pagliara</surname><given-names>D</given-names></string-name>, <string-name><surname>Locatelli</surname><given-names>F</given-names></string-name>. <article-title>Mesenchymal stromal cell therapy: a revolution in regenerative medicine?</article-title><source xml:lang="en">Bone Marrow Transplant</source>. <year>2012</year>;<volume>47</volume>:<fpage>164</fpage>‐<lpage>171</lpage>.<pub-id pub-id-type="pmid">21478914</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0016"><string-name><surname>Chang</surname><given-names>YS</given-names></string-name>, <string-name><surname>Choi</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Sung</surname><given-names>DK</given-names></string-name>, et al. <article-title>Intratracheal transplantation of human umbilical cord blood derived mesenchymal stem cells dose‐dependently attenuates hyperoxia‐induced lung injury in neonatal rats</article-title>. <source xml:lang="en">Cell Transplant</source>. <year>2011</year>;<volume>12</volume>:<fpage>1</fpage>‐<lpage>32</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0017"><string-name><surname>Baber</surname><given-names>SR</given-names></string-name>, <string-name><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name><surname>Master</surname><given-names>RG</given-names></string-name>, et al. <article-title>Intratracheal mesenchymal stem cell administration attenuates monocrotaline‐induced pulmonary hypertension and endothelial dysfunction</article-title>. <source xml:lang="en">Am J Physiol Heart Circ Physiol</source>. <year>2007</year>;<volume>292</volume>:<fpage>H1120</fpage>‐<lpage>H1128</lpage>.<pub-id pub-id-type="pmid">16980338</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0018"><string-name><surname>Sung</surname><given-names>DK</given-names></string-name>, <string-name><surname>Chang</surname><given-names>YS</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>SY</given-names></string-name>, et al. <article-title>Optimal route for human umbilical cord blood‐derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology</article-title>. <source xml:lang="en">PLoS One</source>. <year>2015</year>;<volume>10</volume>:<elocation-id>e0135574</elocation-id>.<pub-id pub-id-type="pmid">26305093</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0019"><string-name><surname>Pierro</surname><given-names>M</given-names></string-name>, <string-name><surname>Ionescu</surname><given-names>L</given-names></string-name>, <string-name><surname>Montemurro</surname><given-names>T</given-names></string-name>, et al. <article-title>Short‐term, long‐term and paracrine effect of human umbilical cord‐derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Thorax</source>. <year>2013</year>;<volume>68</volume>:<fpage>475</fpage>‐<lpage>484</lpage>.<pub-id pub-id-type="pmid">23212278</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0020"><string-name><surname>Balgi‐Agarwal</surname><given-names>S</given-names></string-name>, <string-name><surname>Winter</surname><given-names>C</given-names></string-name>, <string-name><surname>Corral</surname><given-names>A</given-names></string-name>, <string-name><surname>Mustafa</surname><given-names>SB</given-names></string-name>, <string-name><surname>Hornsby</surname><given-names>P</given-names></string-name>, <string-name><surname>Moreira</surname><given-names>A</given-names></string-name>. <article-title>Comparison of preterm and term Wharton's jelly‐derived mesenchymal stem cell properties in different oxygen tensions</article-title>. <source xml:lang="en">Cells Tissues Organs</source>. <year>2018</year>;<volume>205</volume>:<fpage>137</fpage>‐<lpage>150</lpage>.<pub-id pub-id-type="pmid">29949803</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0021"><string-name><surname>Augustine</surname><given-names>S</given-names></string-name>, <string-name><surname>Avey</surname><given-names>MT</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>B</given-names></string-name>, et al. <article-title>Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta‐analysis of preclinical studies</article-title>. <source xml:lang="en">Stem Cells Translational Medicine</source>. <year>2017</year>;<volume>6</volume>:<fpage>2079</fpage>‐<lpage>2093</lpage>.<pub-id pub-id-type="pmid">29045045</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0022"><string-name><surname>Leary</surname><given-names>S</given-names></string-name>, <string-name><surname>Das</surname><given-names>P</given-names></string-name>, <string-name><surname>Ponnalagu</surname><given-names>D</given-names></string-name>, et al. <article-title>Genetic strain and sex differences in a hyperoxia‐induced mouse model of varying severity of bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Am J Pathol</source>. <year>2019</year>;<volume>189</volume>:<fpage>999</fpage>‐<lpage>1014</lpage>.<pub-id pub-id-type="pmid">30794808</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0023"><string-name><surname>Balany</surname><given-names>J</given-names></string-name>, <string-name><surname>Bhandari</surname><given-names>V</given-names></string-name>. <article-title>Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia</article-title>. <source xml:lang="en">Front Med</source>. <year>2015</year>;<volume>2</volume>:<fpage>90</fpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0024"><string-name><surname>Yee</surname><given-names>M</given-names></string-name>, <string-name><surname>Chess</surname><given-names>PR</given-names></string-name>, <string-name><surname>McGrath‐Morrow</surname><given-names>SA</given-names></string-name>, et al. <article-title>Neonatal oxygen adversely affects lung function in adult mice without altering surfactant composition or activity</article-title>. <source xml:lang="en">Am J Physiol Cell Mol Physiol</source>. <year>2009</year>;<volume>297</volume>:<fpage>L641</fpage>‐<lpage>L649</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0025"><string-name><surname>Berger</surname><given-names>J</given-names></string-name>, <string-name><surname>Bhandari</surname><given-names>V</given-names></string-name>. <article-title>Animal models of bronchopulmonary dysplasia. The term mouse models</article-title>. <source xml:lang="en">Am J Physiol Cell Mol Physiol</source>. <year>2014</year>;<volume>307</volume>:<fpage>L936</fpage>‐<lpage>L947</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0026"><string-name><surname>Stewart</surname><given-names>K</given-names></string-name>, <string-name><surname>Schroeder</surname><given-names>VA</given-names></string-name>. <article-title>Rodent identification II</article-title>. <source xml:lang="en">J Vis Exp</source>. <year>2017</year>; <ext-link ext-link-type="uri" xlink:href="http://jove.com/science-education/10189/rodent-identification-i">http://jove.com/science-education/10189/rodent-identification-i</ext-link>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0027"><string-name><surname>Hanson</surname><given-names>LR</given-names></string-name>, <string-name><surname>Fine</surname><given-names>JM</given-names></string-name>, <string-name><surname>Svitak</surname><given-names>AL</given-names></string-name>, <string-name><surname>Faltesek</surname><given-names>KA</given-names></string-name>. <article-title>Intranasal administration of CNS therapeutics to awake mice</article-title>. <source xml:lang="en">J Vis Exp</source>. <year>2013</year>; <ext-link ext-link-type="uri" xlink:href="http://jove.com/video/4440/intranasal-administration-of-cns-therapeutics-to-awake-mice">http://jove.com/video/4440/intranasal-administration-of-cns-therapeutics-to-awake-mice</ext-link>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0028"><string-name><surname>Danielyan</surname><given-names>L</given-names></string-name>, <string-name><surname>Schäfer</surname><given-names>R</given-names></string-name>, <string-name><surname>von Ameln‐Mayerhofer</surname><given-names>A</given-names></string-name>, et al. <article-title>Intranasal delivery of cells to the brain</article-title>. <source xml:lang="en">Eur J Cell Biol</source>. <year>2009</year>;<volume>88</volume>:<fpage>315</fpage>‐<lpage>324</lpage>.<pub-id pub-id-type="pmid">19324456</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0029"><string-name><surname>Galeano</surname><given-names>C</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Mishra</surname><given-names>A</given-names></string-name>, et al. <article-title>The route by which intranasally delivered stem cells enter the central nervous system</article-title>. <source xml:lang="en">Cell Transplant</source>. <year>2018</year>;<volume>27</volume>:<fpage>501</fpage>‐<lpage>514</lpage>.<pub-id pub-id-type="pmid">29756518</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0030"><string-name><surname>Allard</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>K</given-names></string-name>, <string-name><surname>Lopez</surname><given-names>XM</given-names></string-name>, et al. <article-title>Immunohistochemical toolkit for tracking and quantifying xenotransplanted human stem cells</article-title>. <source xml:lang="en">Regen Med</source>. <year>2014</year>;<volume>9</volume>:<fpage>437</fpage>‐<lpage>452</lpage>.<pub-id pub-id-type="pmid">25159062</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0031"><string-name><surname>Jacob</surname><given-names>RE</given-names></string-name>, <string-name><surname>Carson</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gideon</surname><given-names>KM</given-names></string-name>, <string-name><surname>Amidan</surname><given-names>BG</given-names></string-name>, <string-name><surname>Smith</surname><given-names>CL</given-names></string-name>, <string-name><surname>Lee</surname><given-names>KM</given-names></string-name>. <article-title>Comparison of two quantitative methods of discerning airspace enlargement in smoke‐exposed mice</article-title>. <source xml:lang="en">PLoS One</source>. <year>2009</year>;<volume>4</volume>:<elocation-id>e6670</elocation-id>.<pub-id pub-id-type="pmid">19688093</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0032"><string-name><surname>Kim</surname><given-names>KC</given-names></string-name>, <string-name><surname>Lee</surname><given-names>HR</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Cho</surname><given-names>MS</given-names></string-name>, <string-name><surname>Hong</surname><given-names>YM</given-names></string-name>. <article-title>Changes of gene expression after bone marrow cell transfusion in rats with monocrotaline‐induced pulmonary hypertension</article-title>. <source xml:lang="en">J Korean Med Sci</source>. <year>2012</year>;<volume>27</volume>:<fpage>605</fpage>‐<lpage>613</lpage>.<pub-id pub-id-type="pmid">22690090</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0033"><string-name><surname>Thornton</surname><given-names>B</given-names></string-name>, <string-name><surname>Basu</surname><given-names>C</given-names></string-name>. <article-title>Real‐time PCR (qPCR) primer design using free online software</article-title>. <source xml:lang="en">Biochem Mol Biol Educ</source>. <year>2011</year>;<volume>39</volume>:<fpage>145</fpage>‐<lpage>154</lpage>.<pub-id pub-id-type="pmid">21445907</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0034"><string-name><surname>van Haaften</surname><given-names>T</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>R</given-names></string-name>, <string-name><surname>Bonnet</surname><given-names>S</given-names></string-name>, et al. <article-title>Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2009</year>;<volume>180</volume>:<fpage>1131</fpage>‐<lpage>1142</lpage>.<pub-id pub-id-type="pmid">19713449</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0035"><string-name><surname>Monastyrskaya</surname><given-names>K</given-names></string-name>, <string-name><surname>Babiychuk</surname><given-names>EB</given-names></string-name>, <string-name><surname>Draeger</surname><given-names>A</given-names></string-name>. <article-title>The annexins: spatial and temporal coordination of signaling events during cellular stress</article-title>. <source xml:lang="en">Cell Mol Life Sci</source>. <year>2009</year>;<volume>66</volume>:<fpage>2623</fpage>‐<lpage>2642</lpage>.<pub-id pub-id-type="pmid">19381436</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0036"><string-name><surname>Shmilovich</surname><given-names>H</given-names></string-name>, <string-name><surname>Ben‐Shoshan</surname><given-names>J</given-names></string-name>, <string-name><surname>Tal</surname><given-names>R</given-names></string-name>, et al. <article-title>B‐type natriuretic peptide enhances vasculogenesis by promoting number and functional properties of early endothelial progenitor cells</article-title>. <source xml:lang="en">Tissue Eng Part A</source>. <year>2009</year>;<volume>15</volume>:<fpage>2741</fpage>‐<lpage>2749</lpage>.<pub-id pub-id-type="pmid">19275472</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0037"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Mao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Chu</surname><given-names>S</given-names></string-name>, et al. <article-title>Intranasal versus intraperitoneal delivery of human umbilical cord tissue‐derived cultured mesenchymal stromal cells in a murine model of neonatal lung injury</article-title>. <source xml:lang="en">Am J Pathol</source>. <year>2014</year>;<volume>184</volume>:<fpage>3344</fpage>‐<lpage>3358</lpage>.<pub-id pub-id-type="pmid">25455688</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0038"><string-name><surname>Fritzell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Mao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Gundavarapu</surname><given-names>S</given-names></string-name>, et al. <article-title>Fate and effects of adult bone marrow cells in lungs of normoxic and hyperoxic newborn mice</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>2009</year>;<volume>40</volume>:<fpage>575</fpage>‐<lpage>587</lpage>.<pub-id pub-id-type="pmid">18988921</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0039"><string-name><surname>Royce</surname><given-names>SG</given-names></string-name>, <string-name><surname>Rele</surname><given-names>S</given-names></string-name>, <string-name><surname>Broughton</surname><given-names>BRS</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>K</given-names></string-name>, <string-name><surname>Samuel</surname><given-names>CS</given-names></string-name>. <article-title>Intranasal administration of mesenchymoangioblast‐derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease</article-title>. <source xml:lang="en">FASEB J</source>. <year>2017</year>;<volume>31</volume>:<fpage>4168</fpage>‐<lpage>4178</lpage>.<pub-id pub-id-type="pmid">28626025</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0040"><string-name><surname>Southam</surname><given-names>DS</given-names></string-name>, <string-name><surname>Dolovich</surname><given-names>M</given-names></string-name>, <string-name><surname>O'Byrne</surname><given-names>PM</given-names></string-name>, et al. <article-title>Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia</article-title>. <source xml:lang="en">Am J Physiol Cell Mol Physiol</source>. <year>2002</year>;<volume>282</volume>:<fpage>L833</fpage>‐<lpage>L839</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0041"><string-name><surname>Dao</surname><given-names>DT</given-names></string-name>, <string-name><surname>Vuong</surname><given-names>JT</given-names></string-name>, <string-name><surname>Anez‐Bustillos</surname><given-names>L</given-names></string-name>, et al. <article-title>Intranasal delivery of VEGF enhances compensatory lung growth in mice</article-title>. <source xml:lang="en">PLoS One</source>. <year>2018</year>;<volume>13</volume>:<elocation-id>e0198700</elocation-id>.<pub-id pub-id-type="pmid">29879188</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0042"><string-name><surname>Miller</surname><given-names>MA</given-names></string-name>, <string-name><surname>Stabenow</surname><given-names>JM</given-names></string-name>, <string-name><surname>Parvathareddy</surname><given-names>J</given-names></string-name>, et al. <article-title>Visualization of murine intranasal dosing efficiency using luminescent <italic>Francisella tularensis</italic>: effect of instillation volume and form of Anesthesia</article-title>. <source xml:lang="en">PLoS One</source>. <year>2012</year>;<volume>7</volume>:<elocation-id>e31359</elocation-id>.<pub-id pub-id-type="pmid">22384012</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0043"><string-name><surname>Grassin‐Delyle</surname><given-names>S</given-names></string-name>, <string-name><surname>Buenestado</surname><given-names>A</given-names></string-name>, <string-name><surname>Naline</surname><given-names>E</given-names></string-name>, et al. <article-title>Intranasal drug delivery: an efficient and non‐invasive route for systemic administration</article-title>. <source xml:lang="en">Pharmacol Ther</source>. <year>2012</year>;<volume>134</volume>:<fpage>366</fpage>‐<lpage>379</lpage>.<pub-id pub-id-type="pmid">22465159</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0044"><string-name><surname>Balyasnikova</surname><given-names>IV</given-names></string-name>, <string-name><surname>Prasol</surname><given-names>MS</given-names></string-name>, <string-name><surname>Ferguson</surname><given-names>SD</given-names></string-name>, et al. <article-title>Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors</article-title>. <source xml:lang="en">Mol Ther</source>. <year>2014</year>;<volume>22</volume>:<fpage>140</fpage>‐<lpage>148</lpage>.<pub-id pub-id-type="pmid">24002694</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0045"><string-name><surname>Reitz</surname><given-names>M</given-names></string-name>, <string-name><surname>Demestre</surname><given-names>M</given-names></string-name>, <string-name><surname>Sedlacik</surname><given-names>J</given-names></string-name>, et al. <article-title>Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma</article-title>. <source xml:lang="en">Stem Cells Translational Medicine</source>. <year>2012</year>;<volume>1</volume>:<fpage>866</fpage>‐<lpage>873</lpage>.<pub-id pub-id-type="pmid">23283548</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0046"><string-name><surname>Chang</surname><given-names>YS</given-names></string-name>, <string-name><surname>Oh</surname><given-names>W</given-names></string-name>, <string-name><surname>Choi</surname><given-names>SJ</given-names></string-name>, et al. <article-title>Human umbilical cord blood‐derived mesenchymal stem cells attenuate hyperoxia‐induced lung injury in neonatal rats</article-title>. <source xml:lang="en">Cell Transplant</source>. <year>2009</year>;<volume>18</volume>:<fpage>869</fpage>‐<lpage>886</lpage>.<pub-id pub-id-type="pmid">19500472</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0047"><string-name><surname>Abman</surname><given-names>SH</given-names></string-name>. <article-title>Pulmonary vascular disease and bronchopulmonary dysplasia: evaluation and treatment of pulmonary hypertension</article-title>. <source xml:lang="en">Neoreviews</source>. <year>2011</year>;<volume>12</volume>:<elocation-id>e645</elocation-id>‐<elocation-id>e651</elocation-id>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0048"><string-name><surname>Steinhorn</surname><given-names>RH</given-names></string-name>. <article-title>Neonatal pulmonary hypertension</article-title>. <source xml:lang="en">Pediatr Crit Care Med</source>. <year>2010</year>;<volume>11</volume>:<fpage>S79</fpage>‐<lpage>S84</lpage>.<pub-id pub-id-type="pmid">20216169</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0049"><string-name><surname>D'Angio</surname><given-names>CT</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>RM</given-names></string-name>. <article-title>Animal models of bronchopulmonary dysplasia. The preterm and term rabbit models</article-title>. <source xml:lang="en">Am J Physiol Cell Mol Physiol</source>. <year>2014</year>;<volume>307</volume>:<fpage>L959</fpage>‐<lpage>L969</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0050"><string-name><surname>Bui</surname><given-names>CB</given-names></string-name>, <string-name><surname>Pang</surname><given-names>MA</given-names></string-name>, <string-name><surname>Sehgal</surname><given-names>A</given-names></string-name>, et al. <article-title>Pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infants</article-title>. <source xml:lang="en">J Reprod Immunol</source>. <year>2017</year>;<volume>124</volume>:<fpage>21</fpage>‐<lpage>29</lpage>.<pub-id pub-id-type="pmid">29035757</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0051"><string-name><surname>Royce</surname><given-names>SG</given-names></string-name>, <string-name><surname>Nold</surname><given-names>MF</given-names></string-name>, <string-name><surname>Bui</surname><given-names>C</given-names></string-name>, et al. <article-title>Airway remodeling and hyperreactivity in a model of bronchopulmonary dysplasia and their modulation by IL‐1 receptor antagonist</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>2016</year>;<volume>55</volume>:<fpage>858</fpage>‐<lpage>868</lpage>.<pub-id pub-id-type="pmid">27482635</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0052"><string-name><surname>Kuhn</surname><given-names>M</given-names></string-name>. <article-title>Endothelial actions of atrial and B‐type natriuretic peptides</article-title>. <source xml:lang="en">Br J Pharmacol</source>. <year>2012</year>;<volume>166</volume>:<fpage>522</fpage>‐<lpage>531</lpage>.<pub-id pub-id-type="pmid">22220582</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0053"><string-name><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name><surname>Guihard</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, et al. <article-title>Vascular endothelium plays a key role in directing pulmonary epithelial cell differentiation</article-title>. <source xml:lang="en">J Cell Biol</source>. <year>2017</year>;<volume>216</volume>:<fpage>3369</fpage>‐<lpage>3385</lpage>.<pub-id pub-id-type="pmid">28838957</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0054"><string-name><surname>Cooper</surname><given-names>ST</given-names></string-name>, <string-name><surname>McNeil</surname><given-names>PL</given-names></string-name>. <article-title>Membrane repair: mechanisms and pathophysiology</article-title>. <source xml:lang="en">Physiol Rev</source>. <year>2015</year>;<volume>95</volume>:<fpage>1205</fpage>‐<lpage>1240</lpage>.<pub-id pub-id-type="pmid">26336031</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0055"><string-name><surname>Monastyrskaya</surname><given-names>K</given-names></string-name>. <article-title>Functional association between regulatory RNAs and the annexins</article-title>. <source xml:lang="en">Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>:<fpage>591</fpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0056"><string-name><surname>Bouter</surname><given-names>A</given-names></string-name>, <string-name><surname>Gounou</surname><given-names>C</given-names></string-name>, <string-name><surname>Bérat</surname><given-names>R</given-names></string-name>, et al. <article-title>Annexin‐A5 assembled into two‐dimensional arrays promotes cell membrane repair</article-title>. <source xml:lang="en">Nat Commun</source>. <year>2011</year>;<volume>2</volume>:<fpage>270</fpage>.<pub-id pub-id-type="pmid">21468022</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0057"><string-name><surname>Patchell</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Wojcik</surname><given-names>KR</given-names></string-name>, <string-name><surname>Yang</surname><given-names>T‐L</given-names></string-name>, <string-name><surname>White</surname><given-names>SR</given-names></string-name>, <string-name><surname>Dorscheid</surname><given-names>DR</given-names></string-name>. <article-title>Glycosylation and annexin II cell surface translocation mediate airway epithelial wound repair</article-title>. <source xml:lang="en">Am J Physiol Cell Mol Physiol</source>. <year>2007</year>;<volume>293</volume>:<fpage>L354</fpage>‐<lpage>L363</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0058"><string-name><surname>Shi</surname><given-names>M</given-names></string-name>, <string-name><surname>Liu</surname><given-names>ZW</given-names></string-name>, <string-name><surname>Wang</surname><given-names>FS</given-names></string-name>. <article-title>Immunomodulatory properties and therapeutic application of mesenchymal stem cells</article-title>. <source xml:lang="en">Clin Exp Immunol</source>. <year>2011</year>;<volume>164</volume>:<fpage>1</fpage>‐<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0059"><string-name><surname>Gao</surname><given-names>F</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>SM</given-names></string-name>, <string-name><surname>Motan</surname><given-names>DAL</given-names></string-name>, et al. <article-title>Mesenchymal stem cells and immunomodulation: current status and future prospects</article-title>. <source xml:lang="en">Cell Death Dis</source>. <year>2016</year>;<volume>7</volume>:<elocation-id>e2062</elocation-id>.<pub-id pub-id-type="pmid">26794657</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0060"><string-name><surname>Boshuizen</surname><given-names>MCS</given-names></string-name>, <string-name><surname>Steinberg</surname><given-names>GK</given-names></string-name>. <article-title>Stem cell‐based immunomodulation after stroke: effects on brain repair processes</article-title>. <source xml:lang="en">Stroke</source>. <year>2018</year>;<volume>49</volume>:<fpage>1563</fpage>‐<lpage>1570</lpage>.<pub-id pub-id-type="pmid">29724892</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0061"><string-name><surname>Nauta</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Fibbe</surname><given-names>WE</given-names></string-name>. <article-title>Immunomodulatory properties of mesenchymal stromal cells</article-title>. <source xml:lang="en">Blood</source>. <year>2007</year>;<volume>110</volume>:<fpage>3499</fpage>‐<lpage>3506</lpage>.<pub-id pub-id-type="pmid">17664353</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0062"><string-name><surname>Chang</surname><given-names>YS</given-names></string-name>, <string-name><surname>Choi</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>SY</given-names></string-name>, et al. <article-title>Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury</article-title>. <source xml:lang="en">PLoS One</source>. <year>2013</year>;<volume>8</volume>:<elocation-id>e52419</elocation-id>.<pub-id pub-id-type="pmid">23349686</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0063"><string-name><surname>Monsel</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gennai</surname><given-names>S</given-names></string-name>, <string-name><surname>Hao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JW</given-names></string-name>. <article-title>Cell‐based therapy for acute organ injury</article-title>. <source xml:lang="en">Anesthesiology</source>. <year>2014</year>;<volume>121</volume>:<fpage>1099</fpage>‐<lpage>1121</lpage>.<pub-id pub-id-type="pmid">25211170</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0064"><string-name><surname>Zou</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>Z</given-names></string-name>, et al. <article-title>Microvesicles derived from human Wharton's jelly mesenchymal stromal cells ameliorate renal ischemia‐reperfusion injury in rats by suppressing CX3CL1</article-title>. <source xml:lang="en">Stem Cell Res Ther</source>. <year>2014</year>;<volume>5</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">24646750</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0065">
                <label>65</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0065"><string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Sanmamed</surname><given-names>MF</given-names></string-name>, <string-name><surname>Datar</surname><given-names>I</given-names></string-name>, et al. <article-title>Fibrinogen‐like protein 1 is a major immune inhibitory ligand of LAG‐3</article-title>. <source xml:lang="en">Cell</source>. <year>2019</year>;<volume>176</volume>:<fpage>334</fpage>‐<lpage>347.e12</lpage>.<pub-id pub-id-type="pmid">30580966</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0066">
                <label>66</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0066"><string-name><surname>Jeon</surname><given-names>GW</given-names></string-name>, <string-name><surname>Sung</surname><given-names>DK</given-names></string-name>, <string-name><surname>Jung</surname><given-names>YJ</given-names></string-name>, et al. <article-title>Granulocyte colony stimulating factor attenuates hyperoxia‐induced lung injury by down‐modulating inflammatory responses in neonatal rats</article-title>. <source xml:lang="en">Yonsei Med J</source>. <year>2011</year>;<volume>52</volume>:<fpage>65</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">21155037</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0067">
                <label>67</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0067"><string-name><surname>Dempsey</surname><given-names>EC</given-names></string-name>, <string-name><surname>Wick</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Karoor</surname><given-names>V</given-names></string-name>, et al. <article-title>Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia</article-title>. <source xml:lang="en">Am J Pathol</source>. <year>2009</year>;<volume>174</volume>:<fpage>782</fpage>‐<lpage>796</lpage>.<pub-id pub-id-type="pmid">19234135</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0068">
                <label>68</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0068"><string-name><surname>Walter</surname><given-names>J</given-names></string-name>, <string-name><surname>Ware</surname><given-names>LB</given-names></string-name>, <string-name><surname>Matthay</surname><given-names>MA</given-names></string-name>. <article-title>Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis</article-title>. <source xml:lang="en">Lancet Respir Med</source>. <year>2014</year>;<volume>2</volume>:<fpage>1016</fpage>‐<lpage>1026</lpage>.<pub-id pub-id-type="pmid">25465643</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0069">
                <label>69</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0069"><string-name><surname>Caley</surname><given-names>MP</given-names></string-name>, <string-name><surname>Martins</surname><given-names>VLC</given-names></string-name>, <string-name><surname>O'Toole</surname><given-names>EA</given-names></string-name>. <article-title>Metalloproteinases and wound healing</article-title>. <source xml:lang="en">Adv Wound Care</source>. <year>2015</year>;<volume>4</volume>:<fpage>225</fpage>‐<lpage>234</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0070">
                <label>70</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0070"><string-name><surname>Akita</surname><given-names>S</given-names></string-name>, <string-name><surname>Daian</surname><given-names>T</given-names></string-name>, <string-name><surname>Ishihara</surname><given-names>H</given-names></string-name>, <string-name><surname>Fujii</surname><given-names>T</given-names></string-name>, <string-name><surname>Akino</surname><given-names>K</given-names></string-name>. <article-title>Leukemia inhibitory factor‐transfected embryonic fibroblasts and vascular endothelial growth factor successfully improve the skin substitute wound healing by increasing angiogenesis and matrix production</article-title>. <source xml:lang="en">J Dermatol Sci</source>. <year>2004</year>;<volume>36</volume>:<fpage>11</fpage>‐<lpage>23</lpage>.<pub-id pub-id-type="pmid">15488701</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0071">
                <label>71</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0071"><string-name><surname>Foronjy</surname><given-names>RF</given-names></string-name>, <string-name><surname>Dabo</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Cummins</surname><given-names>N</given-names></string-name>, <string-name><surname>Geraghty</surname><given-names>P</given-names></string-name>. <article-title>Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection</article-title>. <source xml:lang="en">BMC Immunol</source>. <year>2014</year>;<volume>15</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">25277705</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0072">
                <label>72</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0072"><string-name><surname>Chromy</surname><given-names>BA</given-names></string-name>, <string-name><surname>Eldridge</surname><given-names>A</given-names></string-name>, <string-name><surname>Forsberg</surname><given-names>JA</given-names></string-name>, et al. <article-title>Wound outcome in combat injuries is associated with a unique set of protein biomarkers</article-title>. <source xml:lang="en">J Transl Med</source>. <year>2013</year>;<volume>11</volume>:<fpage>281</fpage>.<pub-id pub-id-type="pmid">24192341</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0073">
                <label>73</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0073"><string-name><surname>Olczyk</surname><given-names>P</given-names></string-name>, <string-name><surname>Mencner</surname><given-names>Ł</given-names></string-name>, <string-name><surname>Komosinska‐Vassev</surname><given-names>K</given-names></string-name>. <article-title>The role of the extracellular matrix components in cutaneous wound healing</article-title>. <source xml:lang="en">Biomed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<fpage>1</fpage>‐<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0074">
                <label>74</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0074"><string-name><surname>Kathiriya</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Nakra</surname><given-names>N</given-names></string-name>, <string-name><surname>Nixon</surname><given-names>J</given-names></string-name>, et al. <article-title>Galectin‐1 inhibition attenuates profibrotic signaling in hypoxia‐induced pulmonary fibrosis</article-title>. <source xml:lang="en">Cell Death Discov</source>. <year>2017</year>;<volume>3</volume>:<fpage>17010</fpage>.<pub-id pub-id-type="pmid">28417017</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0075">
                <label>75</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0075"><string-name><surname>Mabotuwana</surname><given-names>N</given-names></string-name>, <string-name><surname>Murtha</surname><given-names>L</given-names></string-name>, <string-name><surname>Hardy</surname><given-names>S</given-names></string-name>, <string-name><surname>Boyle</surname><given-names>A</given-names></string-name>. <article-title>Fibulin‐3 in cardiac fibrosis</article-title>. <source xml:lang="en">Hear Lung Circ</source>. <year>2017</year>;<volume>26</volume>:<fpage>S133</fpage>.</mixed-citation>
              </ref>
              <ref id="sct312626-bib-0076">
                <label>76</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0076"><string-name><surname>Venkatesan</surname><given-names>B</given-names></string-name>, <string-name><surname>Prabhu</surname><given-names>SD</given-names></string-name>, <string-name><surname>Venkatachalam</surname><given-names>K</given-names></string-name>, et al. <article-title>WNT1‐inducible signaling pathway protein‐1 activates diverse cell survival pathways and blocks doxorubicin‐induced cardiomyocyte death</article-title>. <source xml:lang="en">Cell Signal</source>. <year>2010</year>;<volume>22</volume>:<fpage>809</fpage>‐<lpage>820</lpage>.<pub-id pub-id-type="pmid">20074638</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0077">
                <label>77</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0077"><string-name><surname>Venkatachalam</surname><given-names>K</given-names></string-name>, <string-name><surname>Venkatesan</surname><given-names>B</given-names></string-name>, <string-name><surname>Valente</surname><given-names>AJ</given-names></string-name>, et al. <article-title>WISP1, a pro‐mitogenic, pro‐survival factor, mediates tumor necrosis factor‐α (TNF‐α)‐stimulated cardiac fibroblast proliferation but inhibits TNF‐α‐induced cardiomyocyte death</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2009</year>;<volume>284</volume>:<fpage>14414</fpage>‐<lpage>14427</lpage>.<pub-id pub-id-type="pmid">19339243</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0078">
                <label>78</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0078"><string-name><surname>Pritzker</surname><given-names>LB</given-names></string-name>, <string-name><surname>Scatena</surname><given-names>M</given-names></string-name>, <string-name><surname>Giachelli</surname><given-names>CM</given-names></string-name>. <article-title>The role of osteoprotegerin and tumor necrosis factor‐related apoptosis‐inducing ligand in human microvascular endothelial cell survival</article-title>. <source xml:lang="en">Mol Biol Cell</source>. <year>2004</year>;<volume>15</volume>:<fpage>2834</fpage>‐<lpage>2841</lpage>.<pub-id pub-id-type="pmid">15064358</pub-id></mixed-citation>
              </ref>
              <ref id="sct312626-bib-0079">
                <label>79</label>
                <mixed-citation publication-type="journal" id="sct312626-cit-0079"><string-name><surname>Ben‐Jonathan</surname><given-names>N</given-names></string-name>, <string-name><surname>LaPensee</surname><given-names>CR</given-names></string-name>, <string-name><surname>LaPensee</surname><given-names>EW</given-names></string-name>. <article-title>What can we learn from rodents about prolactin in humans?</article-title><source xml:lang="en">Endocr Rev</source>. <year>2008</year>;<volume>29</volume>:<fpage>1</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">18057139</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
